Editor - Ankur Sharma | The University of Oklahoma | 26897
ISSN: 2167-065X

Clinical Pharmacology & Biopharmaceutics
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Recommended Conferences

34rd World Congress on Pharmacology

Barcelona, Spain
Indexed In
  • CAS Source Index (CASSI)
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Genamics JournalSeek
  • RefSeek
  • Hamdard University
  • OCLC- WorldCat
  • Publons
  • Euro Pub
Share This Page

Ankur Sharma

Ankur Sharma
Editor-In-Chief Ankur Sharma Senior Scientist PPDM QP2 PHARMACOMETRICS
Merck Sharp & Dohme Corp.
New Jersey, United States
The University of Oklahoma


Ankur Sharma obtained his B. Pharm from University of Rajasthan, Jaipur, India and his MS in Pharmacology from Rajiv Gandhi Technical University, Bhopal, India. After his MS he worked as a Research Associate in pre-clinical pharmacology R&D department of Piramal Life Sciences in India. Ankur Sharma has received his Ph.D. in Pharmaceutical Sciences from The University of Oklahoma, Health Sciences Center, College of Pharmacy. He was an ORISE fellow in the Office of Generic Drugs of US FDA in Department of Quantitative Methods & Modeling. Currently he is serving as a Senior Scientist in Quantitative Pharmacology & Pharmacometrics Department of Merck. His most significant research contributions include utilizing quantitative approaches like physiologically based pharmacokinetic modeling, and PK/PD modeling for quantitative prediction of drug levels in tumors with a possibility of human scale-up to enable First-in-Human (FIH) dose selection in cancer patients, determining mechanistic strategies to overcome tumor-resistance in ovarian cancer, bioanalytical method development for analysis of anti-cancer drugs in human plasma, utilizing PBPK approaches for ocular drug translation from animal data to predict human ocular PK and PD, and developing prodrugs for NSAIDs for improved efficacy and safety.

Research Interest

Bioanalytical Method Development, PBPK Modeling, PK/PD modeling, Population Based PK Modeling, Cancer cell biology, Immunology.